Lung cancer trials in Denmark

In Denmark 64 Also abroad 2733

64 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Copenhagen Oe
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Aarhus N, Copenhagen Oe, Soenderborg
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Herning, Vejle
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aarhus N, Herlev, København Ø, Køge, Sønderborg
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Aarhus N, Copenhagen Oe, Herlev, Koege, Odense C
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 1/2Taking people
A 2-part Phase 1/2 Open-label Trial on ODM-212
Where
Aalborg, Copenhagen
Age
18 years and over
People
229 worldwide
Run by
Orion Corporation, Orion Pharma
See details and how to joinNCT07563738
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Roskilde
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Aalborg, Herning, Odense C
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Roskilde
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Soenderborg, Vejle
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1Taking people
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
Where
Odense C
Age
18 years and over
People
214 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05067283 · EU 2022-501563-40-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Odense C, Roskilde
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
No phaseTaking people
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
Where
Aalborg, Herlev, Odense
Age
18 years and over
People
80
Run by
Aalborg University Hospital
See details and how to joinNCT07185958
Phase 1/2Taking people
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Where
Copenhagen, Odense
Age
18 years and over
People
450 worldwide
Run by
Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Copenhagen Oe
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
No phaseTaking people
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
Where
Aalborg, Aarhus N, Copenhagen, Odense
Age
18 years and over
People
182
Run by
Aarhus University Hospital
See details and how to joinNCT07432802
Phase 3Taking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Herlev, Vejle
Age
18 years and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00 · EU 2025-522818-23-00
Phase 1/2Taking people
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Where
Copenhagen Oe, Odense C
Age
18 years and over
People
616 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00
Phase 1/2Taking people
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Where
Copenhagen
Age
18 years and over
People
554 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Odense C
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Århus, Copenhagen Oe, Herlev, Herning, Roskilde, Soenderborg
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 · EU 2024-518365-10-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Aarhus N, Herlev, Odense C
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
No phaseTaking people
Risk-Based Lung Cancer Detection in COPD Patients
Where
Vejle
Age
50 years and over
People
1,000
Run by
Vejle Hospital
See details and how to joinNCT07848815
Phase 2Not yet taking people in Denmark
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
Where
Aarhus N, Copenhagen Oe, Herlev, Koege, Odense C
Age
18 years and over
People
300 worldwide
Run by
Oslo Universitetssykehus HF
See details and how to join2025-524439-38-00 · EU 2025-524439-38-00